PhD, Epidemiology
MSPH, Epidemiology
University of North Carolina at Chapel Hill, Chapel Hill, NC
BS, Neuroscience
Brigham Young University at Provo, Provo, UT
Bradley Layton leads studies using existing healthcare data to evaluate the use, safety, and effectiveness of pharmaceuticals, vaccines, and other medical products. He has considerable leadership experience in the design, conduct, analysis, and reporting of epidemiologic studies and over a decade of experience in the field of pharmacoepidemiology. His experience and publications span a wide range of substantive areas, including renal, cardiovascular, men’s health, vaccines, rare diseases, and pregnancy, and incorporate multidatabase and multinational studies. He has been a project leader or scientific contributor within international consortia of researchers, including the FDA BEST Initiative and Vac4EU. Dr. Layton also has experience with epidemiologic methods, lecturing to clinical and public health audiences about observational study design, large database utilization, and propensity score analysis.
Prior to joining RTI HS, he was a member of the faculty in the Pharmacoepidemiology Program in the University of North Carolina Department of Epidemiology and is currently an adjunct associate professor at the University of North Carolina. Dr. Layton is a fellow and an active member of the International Society of Pharmacoepidemiology, having served on the Scientific Program Committee as the chair of the spotlight poster sessions, on the Public Policy Committee, and as the Chair of the Vaccine Special Interest Group.